Patents by Inventor Morio Ueno
Morio Ueno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11839618Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: GrantFiled: October 9, 2015Date of Patent: December 12, 2023Assignees: SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
-
A STORAGE METHOD OF HUMAN CORNEAL ENDOTHELIAL CELLS AND/OR HUMAN CORNEAL ENDOTHELIAL PRECURSOR CELLS
Publication number: 20230380417Abstract: Human corneal endothelial cells and/or human corneal endothelial precursor cells are preserved with a high survival rate of these cells being maintained, and the occurrence rate of contaminated cells in post-preservation culturing is suppressed. A storage method of human corneal endothelial cells and/or human corneal endothelial precursor cells is characterized in that human corneal endothelial cells and/or human corneal endothelial precursor cells that have been cultured using a culture medium that contains a ROCK inhibitor, and in which the content of epidermal growth factor (EGF) is less than a concentration that will cause a transformation are harvested at a timing when any one of or a plurality of the conditions (a)˜(d) have been met, and are placed in a suspension state and then preserved.Type: ApplicationFiled: October 19, 2021Publication date: November 30, 2023Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Shigeru KINOSHITA, Munetoyo TODA, Chie SOTOZONO, Morio UENO -
Publication number: 20230257700Abstract: To provide a cell trait assay technique for identifying cultured human corneal endothelium cells of which early clinical effect manifestation and a long-term stable clinical effect are confirmed, in clinical trials. Provided is a method of manufacturing a functional human corneal endothelial cell capable of eliciting a human corneal function when infused into an anterior chamber of a human eye, the method comprising the step of proliferating and/or differentiating or maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress, such as proliferation stress.Type: ApplicationFiled: February 26, 2021Publication date: August 17, 2023Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Shigeru KINOSHITA, Junji HAMURO, Chie SOTOZONO, Morio UENO, Munetoyo TODA
-
Publication number: 20230221332Abstract: A method for diagnosing the risk of glaucoma development, which can diagnose the risk of glaucoma development at the pre-disease stage, and to provide a new method to diagnose disease progression in the end-stage glaucoma. The method can include, for example, a diagnosing method for the risk of an ocular disease development or for the disease progression of an end-stage ocular disease by molecular profile analysis of the ocular anterior tissue microenvironment, comprising a step of measuring the concentration level of a metabolite appearing in the collected aqueous humor specimens by mass spectrometry (MS).Type: ApplicationFiled: June 7, 2021Publication date: July 13, 2023Applicants: SHIMADZU CORPORATION, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Morio UENO, Junji HAMURO, Kengo YOSHII, Chie SOTOZONO, Kazuhiro SONOMURA, Taka-Aki SATO
-
Publication number: 20230214998Abstract: A cell evaluation method evaluates the quality of a cell population including a plurality of cells. The cell evaluation method comprises: an index calculation step of calculating an index, based on a captured image of the cell population, the index including at least any one of an average distance representing a packing degree of the cells, a spring constant representing a degree of consistency in distances between the cells, and a hexagonal order parameter representing a degree to which an arrangement of the cells resembles a regular hexagon; and an evaluation step of evaluating the cell population, based on the index calculated in the index calculation step.Type: ApplicationFiled: July 29, 2022Publication date: July 6, 2023Applicants: Kyoto University, Kyoto Prefectural Public University CorporationInventors: Motomu Tanaka, Akihisa Yamamoto, Morio Ueno, Junji Hamuro, Shigeru Kinoshita, Hiroshi Tanaka, Munetoyo Toda, Chie Sotozono
-
Publication number: 20230210864Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: ApplicationFiled: March 13, 2023Publication date: July 6, 2023Applicants: Senju Pharmaceutical Co., Ltd.Inventors: Noriko KOIZUMI, Shigeru KINOSHITA, Morio UENO
-
Patent number: 11633404Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: GrantFiled: October 9, 2015Date of Patent: April 25, 2023Assignees: SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
-
Cell evaluation method, cell evaluation device, and recording medium storing cell evaluation program
Patent number: 11436719Abstract: A cell evaluation method evaluates the quality of a cell population including a plurality of cells. The cell evaluation method comprises: an index calculation step of calculating an index, based on a captured image of the cell population, the index including at least any one of an average distance representing a packing degree of the cells, a spring constant representing a degree of consistency in distances between the cells, and a hexagonal order parameter representing a degree to which an arrangement of the cells resembles a regular hexagon; and an evaluation step of evaluating the cell population, based on the index calculated in the index calculation step.Type: GrantFiled: February 15, 2018Date of Patent: September 6, 2022Assignees: Kyoto University, Kyoto Prefectural Public University CorporationInventors: Motomu Tanaka, Akihisa Yamamoto, Morio Ueno, Junji Hamuro, Shigeru Kinoshita, Hiroshi Tanaka, Munetoyo Toda, Chie Sotozono -
Publication number: 20210140965Abstract: The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.Type: ApplicationFiled: December 23, 2020Publication date: May 13, 2021Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, ACTUALEYES INC., CORNEAGEN, INC.Inventors: Noriko Koizumi, Naoki Okumura, Hiroatsu HIRANO, Shigeru Kinoshita, Morio UENO
-
Publication number: 20210046124Abstract: The present invention complete a technique of treating a corneal disorder or disease by infusion into an anterior chamber of human eyes. Specifically, the present invention based on the findings discovered that cultured human corneal endothelial cells are comprised of a plurality of subpopulations, most of them are not suitable for infusion into patients. The above-described subject was overcome by providing, as a medicament, functionally high grade quality of cells having the function of mature differentiated human corneal endothelial cells which is a specific subpopulation and characterized by their biochemical and functional phenotypes. The present invention provides such a functional mature differentiated corneal endothelial cells, medicament comprising the same, and manufacturing method, quality control and techniques related thereto.Type: ApplicationFiled: October 20, 2020Publication date: February 18, 2021Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Shigeru KINOSHITA, Junji HAMURO, Chie SOTOZONO, Morio UENO
-
Patent number: 10908161Abstract: The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.Type: GrantFiled: July 28, 2014Date of Patent: February 2, 2021Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, ACTUALEYES INC., CORNEAGEN. INC.Inventors: Noriko Koizumi, Naoki Okumura, Hiroatsu Hirano, Shigeru Kinoshita, Morio Ueno
-
Publication number: 20200234433Abstract: A cell evaluation method evaluates the quality of a cell population including a plurality of cells. The cell evaluation method comprises: an index calculation step of calculating an index, based on a captured image of the cell population, the index including at least any one of an average distance representing a packing degree of the cells, a spring constant representing a degree of consistency in distances between the cells, and a hexagonal order parameter representing a degree to which an arrangement of the cells resembles a regular hexagon; and an evaluation step of evaluating the cell population, based on the index calculated in the index calculation step.Type: ApplicationFiled: February 15, 2018Publication date: July 23, 2020Applicants: Kyoto University, Kyoto Prefectural Public University CorporationInventors: Motomu Tanaka, Akihisa Yamamoto, Morio Ueno, Junji Hamuro, Shigeru Kinoshita, Hiroshi Tanaka, Munetoyo Toda, Chie Sotozono
-
Publication number: 20160266114Abstract: The purpose of the present invention is to provide a method of purification and preparation of cultured corneal endothelial cells, and in particular, to provide cell surface markers for use in corneal endothelial cells not including transformed cells. Provided are cell markers for distinguishing normal cells and transformed cells, in particular normal and transformed corneal endothelium cells. These cell markers relate to specific cell surface markers, for example, to a normal corneal endothelial surface marker such as CD166, and a transformed cell surface marker such as CD73. By using the transformed cell surface marker such as CD73 to remove transformed cells by sorting, it becomes possible to improve purity of a normal cultured corneal endothelium. By using normal corneal endothelial surface marker such as CD166, or by combined use with the transformed cell surface marker, it becomes possible to provide a means for verifying the purity of a prepared corneal endothelium.Type: ApplicationFiled: July 28, 2014Publication date: September 15, 2016Inventors: Noriko KOIZUMI, Naoki OKUMURA, Hiroatsu HIRANO, Shigeru KINOSHITA, Morio UENO
-
Publication number: 20160101113Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: ApplicationFiled: October 9, 2015Publication date: April 14, 2016Inventors: Noriko KOIZUMI, Shigeru KINOSHITA, Morio UENO
-
Publication number: 20160030410Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: ApplicationFiled: October 9, 2015Publication date: February 4, 2016Inventors: Noriko KOIZUMI, Shigeru KINOSHITA, Morio UENO
-
Patent number: 9248125Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: GrantFiled: August 28, 2008Date of Patent: February 2, 2016Assignees: Senju Pharmaceutical Co., Ltd.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
-
Publication number: 20130275349Abstract: Provided is a technique for determining a physiological attribute in a mammal, including the onset or progression of human glaucoma, with high accuracy. The results of the determination of genotype date and the results of the determination of cytokine date are consolidated by a consolidated determination unit (114); comparison is made for determining as to which is larger, the number of Case determination procedures or the number of control determination procedures (S330); and it is determined as Case (glaucoma) when the number of Case determination procedures is larger and it is determined as Control (normal person) when the number of Control determination procedures is larger.Type: ApplicationFiled: December 28, 2011Publication date: October 17, 2013Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Kei Tashiro, Shigeru Kinoshita, Tomohito Yagi, Masakazu Nakano, Kazuhiko Mori, Yoko Ikeda, Morio Ueno, Yuichi Tokuda, Katsumi Yagi, Kengo Yoshii, Masahiro Fuwa
-
Patent number: 7923246Abstract: The present invention provides a clinically applicable method of inducing differentiation of the embryonic stem cells. Specifically, the present invention provides a method of culturing embryonic stem cells, which comprises culturing embryonic stem cells in the presence of an amnion-derived factor, a cell culture obtained by the culture method, and a culture agent/culture kit of embryonic stem cells comprising an amnion-derived factor. The present invention also provides a method of screening an amnion-derived factor having an activity useful for culturing embryonic stem cells with the activity as an index, and an amniocyte-derived factor obtained by the screening method. Furthermore, the present invention provides a method of preparing amniocytes useful for culturing embryonic stem cells, amniocytes obtained by the preparation method, and the like.Type: GrantFiled: May 27, 2005Date of Patent: April 12, 2011Assignee: RikenInventors: Yoshiki Sasai, Morio Ueno, Shigeru Kinoshita
-
Publication number: 20100209402Abstract: The invention provides an agent for promoting adhesion of a corneal endothelial cell, containing a Rho kinase inhibitor, as well as a culture medium for a corneal endothelial cell, a solution for preservation of cornea, and a method of producing a corneal endothelial preparation, which includes culturing the corneal endothelial cell using the aforementioned culture medium.Type: ApplicationFiled: August 28, 2008Publication date: August 19, 2010Applicants: SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Shigeru Kinoshita, Morio Ueno
-
Publication number: 20100167398Abstract: Provided are a method of culturing pluripotent stem cells in the presence of a decidua-derived cell or an extracellular matrix derived from the cell, that enables safe and efficient maintenance culture and derivation of pluripotent stem cells; a culture agent for pluripotent stem cells, that comprises a decidua-derived cell or an extracellular matrix derived from the cell; and other means for developing or performing the method.Type: ApplicationFiled: December 23, 2009Publication date: July 1, 2010Applicant: RIKENInventors: Yoshiki SASAI, Tomoko NAGASE, Morio UENO, Yonehiro KANEMURA